Most antidepressants elicit their therapeutic benefits through selective blockade of Na + /Cl − -coupled neurotransmitter transporters. Here we report X-ray structures of the Drosophila melanogaster dopamine transporter in complexes with the polycyclic antidepressants nisoxetine or reboxetine. The inhibitors stabilize the transporter in an outward-open conformation by occupying the substrate-binding site. These structures explain how interactions between the binding pocket and substituents on the aromatic rings of antidepressants modulate drug-transporter selectivity.
The release of biogenic amines-dopamine (DA), norepinephrine (NE) and serotonin (5-HT)-underlies signaling of neural pathways in the central and peripheral nervous systems, thus regulating mood, alertness, motor function and reward-seeking behavior 1 . After their release, the neurotransmitters are cleared from synaptic and extrasynaptic spaces by biogenic amine transporters (BATs), integral-membrane symporters that couple neurotransmitter uptake to Na + /Cl − electrochemical gradients across cell membranes 2 . Owing to the central role of BATs in controlling the extracellular concentrations of neurotransmitters available for receptor binding, BATs are logical targets for small molecules including psychostimulants, such as cocaine and amphetamines, and therapeutic agents, including antidepressants and antianxiety medications 3 .
Many clinically prescribed inhibitors of 5-HT and NE uptake act by elevating the concentrations of the neurotransmitters in extracellular spaces, and in so doing they alleviate conditions that can include depression, anxiety, attention deficit hyperactivity disorder (ADHD), narcolepsy and neuropathic pain 3 . Early discoveries in treating depressive disorders correlated the ability of tricyclic antidepressants (TCAs), such as imipramine, to treat depression through inhibition of catecholamine uptake 4 . More recently, drugs with increased specificity, in the form of selective serotonin-reuptake inhibitors (SSRIs) and serotonin-and norepinephrine-reuptake inhibitors (SNRIs), have replaced TCAs as the preferred agents to treat depression 5 . The treatment of affective disorders through increased neurotransmitter levels constitutes the 'monoamine hypothesis' , which describes the relationship between monoamine signaling and mood disorders 6 . In this study, we report the X-ray crystal structures of the D. melanogaster dopamine transporter (dDAT) in complex with the specific NE-uptake inhibitors nisoxetine and reboxetine-structures that yield insight into the molecular basis for inhibitor specificity.
The dDAT has relatively broad substrate specificity, transporting DA, NE and tyramine with varying efficacies, and it is sensitive to a multitude of inhibitors that act on human biogenic amine transporters 7 . Indeed, D. melanogaster lacks a dedicated norepinephrine transporter (NET) but retains a 5-HT transporter 7 . Despite a preference to transport DA over NE, the dDAT shows greater sensitivity toward antidepressants and lower affinity for cocaine and amphetamines than mammalian DATs, and it exhibits a pharmacological profile closest to those of mammalian NETs 7 .
We previously solved the X-ray structure of a nortriptyline-bound dDAT, which revealed the ability of TCAs to compete for the substratebinding site and to lock the transporter in an outward-open state 8 rather than acting through a noncompetitive mode of inhibition by binding to the extracellular vestibule 9 . TCAs potently inhibit multiple BATs, a phenomenon that probably underlies TCAs' multiple side effects and that renders these drugs unattractive as a primary medication for depressive disorders. More recently, selective inhibitors of serotonin transporters (SERTs) have been developed and have become widely prescribed antidepressants; these include fluoxetine, escitalopram, sertraline and paroxetine, and they have become widely prescribed antidepressants. By contrast, NET-specific inhibitors such as nisoxetine and reboxetine exhibit high-affinity binding to NET as compared to DAT or SERT 10, 11 , and reboxetine is useful for treatment of panic disorder and ADHD. Despite the importance of BAT inhibitors as therapeutic agents and tools of neuroscience, there is little understanding of how TCAs, SSRIs and SNRIs bind to BATs and of the molecular basis of inhibitor selectivity. We set out to determine the structural basis of NET-specific inhibitor selectivity, using dDAT as a model for human NET.
Nisoxetine and reboxetine differ in chemical structure from classic TCAs in that they have discontinuous aromatic groups that branch from a central chiral carbon (Fig. 1a) , whereas TCAs have a fused tricyclicring framework. The SSRI fluoxetine shares a similar aromatic-ring constellation with nisoxetine, with differences in the position and identity of the pharmacophore on the phenoxy ring. Furthermore, fluoxetine has a p-trifluoromethyl substitution, whereas nisoxetine possesses an o-methoxy group. Similarly to nisoxetine, reboxetine has an o-ethoxy group and a unique morpholine ring that hosts the amine group, with an amine moiety being a conserved feature of both substrates and inhibitors in BATs (Fig. 1a) . Here we provide b r i e F c o m m u n i c at i o n s insight into how these differences in pharmacophores modulate BAT selectivity.
We solved structures of nisoxetine and reboxetine bound to dDAT at a resolution of 3.0 Å, which yield unambiguous views of the inhibitor position in the central binding site (Fig. 1b and Supplementary Table 1 ). The dDAT construct used to crystallize nisoxetine was a thermostabilized variant of wild-type dDAT, dDAT cryst , which was originally used to crystallize the nortriptyline-bound complex and which lacks neurotransmitter-transport activity 8 . By contrast, the dDAT mfc construct used in the reboxetine-bound structure has fewer thermostabilizing mutations and possesses dopamine-transport activity, albeit with lower efficiency than in wild-type dDAT 12 . Despite differences in the constructs used in the crystallographic studies, the structures of nisoxetine-dDAT cryst and reboxetine-DAT mfc differ by an r.m.s. deviation of only 0.5 Å, thus indicating that the thermostabilizing mutations do not grossly alter the conformation of dDAT found in these inhibitor-bound structures.
The antidepressant-bound structures of dDAT exhibit an outwardopen conformation ( Fig. 1c) with the inhibitors lodged in the central, or S1, binding site 13 . The inhibitors of dDAT occupy subsites A, B and C, sites derived from studies on a LeuT variant engineered to mimic eukaryotic BATs (LeuBAT) and to bind the chemical groups of SSRIs and SNRIs 14, 15 . A comparison of dDAT structures bound to the hNET inhibitors nortriptyline 8 , nisoxetine and reboxetine reveals a similar organization of residues interacting with the pharmacophores that enables high-affinity binding despite their distinct chemical structures (Figs. 1d,e and 2a) . The amino groups interact at distances of 2.7-3.0 Å with the carbonyl oxygen of Phe43, although the carboxylate of Asp46 is within 3.6 Å. The cavity occupied by Phe43, Ala44, Phe319 and Ser320 forms subsite A 15 , into which the secondary amine groups of both nisoxetine and reboxetine extend (Fig. 2b) . The bulky morpholine ring is akin to the tropane ring of drugs such as cocaine and to the methylated amine groups of nisoxetine and nortriptyline, in that it sterically prevents inward movements of transmembrane helices (TMs) 1b and 6a, which could close or gate the extracellular vestibule (Fig. 2b) .
All three inhibitors possess two aromatic rings that insert into a hydrophobic cleft bordered by Val120, Tyr123 and Tyr124 in TM3, and Ser422 in TM8 at subsite B; and Phe319 and Phe325 (TM6 linker) at subsite C 15 . Residues constituting subsite B differ between insect and mammalian BATs in that dDAT has polar residues Asp121 and Ser426 at subsite B, whereas both human DAT (hDAT) and human NET (hNET) have glycine and methionine at positions equivalent to 121 and 426, respectively. Substituting the polar residues in subsite B of dDAT with hNET residues D121G and S426M resulted in a threefold enhancement in nisoxetine-binding affinity 12 . Interestingly, the trifluoromethyl group of (R)-fluoxetine and the dichlorophenyl group of sertraline also have been shown to insert into this cavity in cocrystal structures with LeuBAT 15 . Upon generating homology models and analyzing residues making contacts with the inhibitors in dDAT, we observed the binding pocket to be more closely related to the binding site of hNET homology models as compared to hDAT (Fig. 2c and   Supplementary Table 2) , results supporting the similarity between the pharmacological profiles of hNET and dDAT.
Reboxetine and nisoxetine have affinities to hNET that are 130-to 400-fold higher than to hSERT or hDAT, despite the high sequence identity among the three monoamine transporters 11, 16 . In contrast with the p-trifluoromethyl group of the SSRI fluoxetine, the o-positioned substituents of these hNET-specific inhibitors access a hydrophobic cavity, below the plane of the drug, which is lined by residues Ala117, Gly425, Val327 and Ala428 in dDAT and identical residues in hNET (Fig. 2c) . However, our hDAT homology model predicts that this pocket is polar, with serine residues in place of Ala117 and Ala428; the equivalent residues Ser149 and Ser429 in hDAT are likely to lead to less favorable interactions with nisoxetine and reboxetine (Fig. 2b) .
In the hNET homology model, reboxetine complements this pocket more effectively than nisoxetine, owing to the ethoxy group (Fig. 2c) ; this could explain its improved selectivity for hNET over hDAT, as compared to that of nisoxetine 17 .
We next investigated whether the nisoxetine-and reboxetinebound structures could explain stereoisomer-specific effects on the inhibition of hNET. (R)-nisoxetine and (S,S)-reboxetine have greater specificity toward hNET over their stereoisomers 17 , although the difference in apparent affinity between enantiomers of nisoxetine and reboxetine are only three-fold and two-fold, respectively 18, 19 . The affinity of dDAT mfc for (R,R)-reboxetine, the enantiomer used in this study, is 20 nM (Fig. 2a) , a value comparable to the affinity observed for human NET 20 . Because (R,R)-reboxetine and a racemic mixture of (R)-and (S)-nisoxetine were available for structural studies, we used these stereoisomers in our crystallographic experiments. Enantiomers for each antidepressant could be placed into the electron densities in the central substrate-binding site (Supplementary Fig. 1) . Upon modeling the stereoisomers within the densities, we found that specific molecular interactions were not significantly different for either reboxetine or nisoxetine, thus indicating the ability of stereoisomers to inhibit the transporters with subtle variations in efficacies. Although these antidepressant-bound structures cannot identify specific interactions that define the enantiomeric selectivity of hNET, they nonetheless will be useful for modeling studies to explain how the more potent enantiomers are recognized.
The cocrystal structures of dDAT in complex with the NE-specific uptake inhibitors nisoxetine and reboxetine yield insights into the pharmacophores that dictate selectivity toward hNET. Together with the dDAT-nortriptyline complex, these structures support a model in which the bilobed aromatic moieties and extended amine groups of antidepressants are important for generating high-affinity inhibition. Chemical modifications on the aromatic rings of antidepressants encode selectivity between biogenic amine transporters, namely a selectivity away from recognition by hDAT and toward recognition by hNET or hSERT. In particular, the identity and position of substituents on the phenoxy ring distinguish certain hNET and hSERT inhibitors on the basis of the environment of subsite B, as demonstrated by the comparison of o and p substitutions on nisoxetine and fluoxetine, respectively. This study reveals the contacts between residues in the binding pocket of a eukaryotic neurotransmitter transporter and hNET-specific antidepressants, providing an avenue for the structure-directed design of more-selective biogenic amine transport inhibitors.
MeTHods
Methods and any associated references are available in the online version of the paper. ref. 8) ) as a template. Gray sticks and spheres, pocket residues; cylinders, TMs; purple sticks, residues that differ between an hDAT homology model and hNET. Residue numbering follows that of hNET, with equivalent positions in hDAT shown in parentheses. Purple dashed line, residues that dictate specificity toward hNET over other BATs. Nisoxetine and reboxetine are shown as blue and magenta sticks and spheres, respectively.
npg oNLINe MeTHods
Constructs. dDAT constructs used in this study include the following. ts 5 dDAT cryst contains thermostabilizing mutations (V74A V275A V311A L415A G538L), ∆1-20, a deletion in EL2 from ∆164-206 and a thrombin-cleavage site (LVPR|GS) replacing residues 602-607. dDAT mfc contains thermostabilizing mutations (V74A L415A), ∆1-20, a modified deletion in EL2 ∆162-202, and a thrombin site replacing residues 602-607.
Expression and purification. The dDAT constructs were expressed as C-terminal GFP-His 8 fusions with baculovirus-mediated transduction of mammalian HEK-293S GnTI − cells 21, 22 . Membranes harvested from cells after infection were homogenized with 1× TBS (20 mM Tris, pH 8.0 and 150 mM NaCl) and solubilized with a final concentration of 20 mM n-dodecyl β-d-maltoside (DDM) in 1× TBS. Detergent-solubilized material was incubated with cobalt-charged metalaffinity resin and eluted with 1× TBS containing 1 mM DDM, 0.2 mM CHS and 100 mM imidazole, pH 8.0. The GFP-His 8 tag was removed by incubation with thrombin overnight at 4 °C. Thrombin-digested protein was subjected to size-exclusion chromatography through a Superdex 200 10/300 column preequilibrated with buffer containing 20 mM Tris, pH 8.0, 300 mM NaCl, 4 mM decyl β-d-maltoside, 0.2 mM CHS and 0.001% (w/v) 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE). Peak fractions were collected and pooled together. All procedures were carried out at 4 °C.
Fab complexation and crystallization. Antibody fragment (Fab) 9D5 was used to complex with the protein at a molar ratio of 1.2 (Fab):1 (protein) 8 . The solution of Fab-DAT complex was incubated with racemic nisoxetine or (R,R)-reboxetine at 1 mM and concentrated with a 100-kDa-cutoff concentrator to 3-4 mg ml −1 . The concentrated protein was spun down to remove excess drug and insoluble aggregates, and plates were set up by hanging-drop vapor diffusion. Crystals of Fab-DAT complexes grew in 0.1 M glycine, pH 9 and 38% PEG 350 monomethyl ether. Crystals of dDAT mfc were obtained by streak seeding with a cat whisker 7 d after drops were set up. All crystals were grown at 4 °C.
Data collection and structure refinement. Crystals were directly flash cooled in liquid nitrogen. Data were collected at APS (24-IDC). Data were processed with either HKL2000 (ref. 23) or XDS 24 . Molecular replacement was carried out for all data sets with coordinates from PDB 4M48 (ref. 8) with Fab 9D5 and dDAT cryst used as independent search models, with PHASER in the PHENIX suite 25, 26 . Iterative cycles of refinement and manual model building were carried out with PHENIX and COOT 27 , respectively, until the models converged to acceptable levels of R factors and stereochemistry. Homology modeling of hNET and hDAT was done with SWISS-MODEL 28 , with structure-based sequence alignments generated from deposited coordinates (PDB 4M48 (ref. 8) ) for dDAT, in PROMALS3D 29 .
Radiolabel binding. All binding assays were carried out by scintillation proximity assay (SPA) 30 
